Joseph Tedesco, Ph.D.
President, Key Molecular Corp., Toronto, Canada
Phone: 416-876-1500 email: jtedesco@keymolecular.com
Selected Other Courses:
2001: Certification as Mediator, trained for ADR (Alternative Dispute
Resolution) within the Federal Government SR&ED Program; sponsored by
Revenue Canada.
|
SR&ED Claims
Support & Guidance |
Organic Chemistry-
Design Syntheses |
|
Molecular
Pharmacology |
Food Chemistry
Projects |
|
Software Algorithms
|
Contract
Science/Engineering Projects |
1991-2022: Scientific
Consultant to Private Sector & Government.
1.
SR&ED - for Revenue
Canada (CRA): 1993-2003
Over 11
years, performed technical reviews or
audits, as an Outside Science Expert, of "Scientific Research and Experimental
Development" (SR&ED)
Tax Claims for Investment Credits made by Canadian Corporations in the
following sectors:
Generic
drug companies, large and small
Contract
Research or Manufacturing Companies
Biotechnology
companies;
These activities involved
evaluating over one billion dollars in corporate expenditures. Work was also done for the SR&ED
Appeals Branch in Ottawa.
2.
SR&ED - for Private
Sector: Wrote or guided over 40 SR&ED
claims on behalf of companies doing
projects in Mechanical Engineering, Agricultural Science, Software and Food Engineering. Dr.
Tedesco has also successfully filed over 30 SR&ED claims for Key Molecular Corp.
since its founding.
3. Related
Scientific & Forensic Investigations: for the Legal &
Insurance Professions. Critiqued the scientific validity of insurance claims by
private sector companies & individuals. Tested claims that a service or a product
was deficient.
AWARDS
Ontario Mental
Health Fellowship 1974-1978
Annual Research
Fund Award (1976) of the Clarke Institute of Psychiatry (Toronto): "For an outstanding research
dissertation within the field of Mental Health published during 1975";
senior author was Philip Seeman, with co-authors M. Chau‑Wong and K. Wong
and J. Tedesco :
For the world's first
successful demonstration (through binding) of the existence of the dopamine receptor
(P.N.A.S.(U.S.A)
72 4376‑4380, 1975.).
Milestones
as Head of Key Molecular Corp.
1988-Current:
2001-2017: DESIGN, SYNTHESIS & SALE OF MANY NEW
RESEARCH CHEMICALS.
1994-2017: DEVELOPMENT OF SOFTWARE FOR
NOVEL DRUG-DESIGN SYSTEMS.
1992
- 1993: DESIGN AND
SYNTHESIS OF NEW
DRUGS FOR SCHIZOPHRENIA AND
PARKINSONISM.
Partnering
with Allelix Pharmaceuticals & with colleagues at the University of
Toronto.
1990 - 1991: KINETICS OF
IONIC RELEASE FROM
POROUS BIOMATERIALS: Product
Improvement Program for Chinook Corp., a large Canadian company. Built a novel
computer-integrated system for analysis of the temporal pattern of ionic
release from slow-release particles.
Developed
a novel enzymatic assay for choline chloride.
1988 ‑ 1990:
CHOLESTEROL REMOVAL R&D PROJECT:
Development of a commercial technology for the selective extraction of cholesterol from egg‑yolk and dairy foods.
Research
Associate, University of Toronto, Department of Chemistry
1985 - 1987
Function: Head of Biochemistry division in the Chemical
Sensors Group at U of T Mississauga Campus.
Duties and Accomplishments:
1.
Scientific
director of a staff of biochemical
technicians, within a team of 6 scientists. This project was financed by a $3
million contract between Allied-Signal Corp. and the University of Toronto.
2.
Basic research on
biological receptors for the applied development of analytical sensing devices.
Set up new laboratory for this work.
3.
Scientific
Communications: presented findings in seminars and meetings.
Visiting
Professor - Chemistry Department, University of Toronto
1993-1995
worked on new drugs for schizophrenia and parkinsonism, collaborating in organic chemistry projects with Prof. Peter Yates.
Scientific Publications: Listed here